Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maribavir prophylaxis in allogeneic stem cell transplant recipients
NCT00223925Phase 2Completed
- Sponsor
- Takeda
- Start
- Oct 2004
- Primary completion
- Apr 2006
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of maribavir in cytomegalovirus infection (CMV) (4 arms), sponsored by Takeda. Primary endpoint: Clinical safety as measured by the recording of treatment emergent adverse events at 13 weeks. Started Oct 2004; status: completed.
02
Drugs
maribavir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT00223925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00223925.